Literature DB >> 5320823

Relative anticonvulsant potency of primidone; a double blind comparison.

P T White, D Plott, J Norton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5320823     DOI: 10.1001/archneur.1966.00470070035004

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


× No keyword cloud information.
  8 in total

Review 1.  Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

2.  The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures.

Authors:  D Chadwick; D M Turnbull
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

Review 3.  Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures.

Authors:  S Taylor; C Tudur Smith; P R Williamson; A G Marson
Journal:  Cochrane Database Syst Rev       Date:  2001

4.  Recent advances in drug therapy for epilepsy.

Authors:  J Bruni
Journal:  Can Med Assoc J       Date:  1979-04-07       Impact factor: 8.262

5.  Methods of assessment of antiepileptic drugs.

Authors:  N Milligan; A Richens
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

Review 6.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 7.  Drug treatment of epilepsy: a review.

Authors:  D Rosenbloom; A R Upton
Journal:  Can Med Assoc J       Date:  1983-02-01       Impact factor: 8.262

8.  Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat.

Authors:  S Nagaki; N Ratnaraj; P N Patsalos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.